Identification of HLA-A24-restricted CD8 + cytotoxic T-cell epitopes derived from mammaglobin-A, a human breast cancer-associated antigen

Human Immunology

Volumn 73, Issue 1, 2012, Pages 11-16

  Tiriveedhi, Venkataswarup ^a   Sarma, Nayan J ^a   Subramanian, Vijay ^a   Fleming, Timothy P ^a   Gillanders, William E ^a   Mohanakumar, Thallachallour ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; CD8 T cell; HLA A24; Mammaglobin A; Vaccine

Indexed keywords

EPITOPE; HLA A24 ANTIGEN; MAMMAGLOBIN A; TUMOR ANTIGEN;

ANTIGEN BINDING; ANTIGEN DETECTION; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CAUCASIAN; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INDIAN; JAPANESE; MEMBRANE STABILIZATION; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTIGENS, CD8; BINDING, COMPETITIVE; BREAST NEOPLASMS; CANCER VACCINES; CELL LINE, TUMOR; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A24 ANTIGEN; HUMANS; MAMMAGLOBIN A; PROTEIN BINDING; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 84355161543     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2011.10.017     Document Type: Article

References (30)

1. Olin J.J., Muss H.B. New strategies for managing metastatic breast cancer. Oncol Williston Park 2000, 14:629-641.
2. Ada G.L. The immunological principles of vaccination. Lancet 1990, 335:523-526.
3. Bocchia M., Bronte V., Colombo M.P., De Vincentiis A., Di Nicola M., Forni G., et al. Antitumor vaccination: where we stand. Haematologica 2000, 85:1172-1206.
4. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998, 282:476-480.
5. Calarota S., Bratt G., Nordlund S., Hinkula J., Leandersson A.C., Sandström E., et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998, 351:1320-1325.
6. Watson M.A., Fleming T.P. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res 1996, 56:860-865.
7. Watson M.A., Dintzis S., Darrow C.M., Voss L.E., DiPersio J., Jensen R., et al. Mammaglobin expression in primary, metastatic, and occult breast cancer. Cancer Res 1999, 59:3028-3031.
8. Finn O.J., Jerome K.R., Henderson R.A., Pecher G., Domenech N., Magarian-Blander J., et al. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 1995, 145:61-89.
9. Peoples G.E., Goedegebuure P.S., Smith R., Linehan D.C., Yoshino I., Eberlein T.J. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci U S A 1995, 92:432-436.
10. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
11. Lohrisch C., Piccart M. HER2/neu as a predictive factor in breast cancer. Clin Breast Cancer 2001, 2:129-135.
12. Narayanan K., Jaramillo A., Benshoff N.D., Campbell L.G., Fleming T.P., Dietz J.R., et al. Response of established human breast tumors to vaccination with mammaglobin-A cDNA. J Natl Cancer Inst 2004, 96:1388-1396.
13. + T cell epitopes derived from mammaglobin-A, a tumor-associated antigen of human breast cancer. Int J Cancer 2002, 102:499-506.
14. + cytotoxic T lymphocytes from breast cancer patients. Breast Cancer Res Treat 2004, 88:29.
15. + cytotoxic T cell epitopes derived from mammaglobin-A expressed on human breast cancers. Breast Cancer Res Treat 2011, 127:81-89.
16. Date Y., Kimura A., Kato H., Sasazuki T. DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese. Tissue Antigens 1996, 47:93-101.
17. Kuhns J.J., Batalia M.A., Yan S., Collins E.J. Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide. J Biol Chem 1999, 274:36422-36427.
18. Tanaka Y., Amos K.D., Joo H.G., Eberlein T.J., Goedegebuure P.S. Modification of the HER2/NEU-derived tumor antigen GP2 improves induction of GP2-reactive cytotoxic T lymphocytes. Int J Cancer 2001, 94:540-544.
19. Oaks M.K., Hanson J.P., O'Malley D.P. Molecular cytogenetic mapping of the human melanoma antigen (MAGE) gene family to chromosome region Xq27-qter: implications for MAGE immunotherapy. Cancer Res 1994, 54:1627-1629.
20. Tykodi S.S., Thompson J.A. Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer. Expert Opin Biol Ther 2008, 8:1947-1953.
21. Sato Y., Roman M., Tighe H., Lee D., Corr M., Nguyen M.D., et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996, 273:352-354.
22. Ulmer J.B., Deck R.R., Dewitt C.M., Donnhly J.I., Liu M.A. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology 1996, 89:59-67.
23. Zöller M., Christ O. Prophylactic tumor vaccination: comparison of effector mechanisms initiated by protein versus DNA vaccination. J Immunol 2001, 166:3440-3450.
24. Bousso P. Generation of MHC-peptide tetramers: a new opportunity for dissecting T-cell immune responses. Microbes Infect 2000, 2:425-429.
25. +T cells in breast cancer immunity following mammaglobin-A DNA vaccination using HLA-class-I tetramers. Breast Cancer Res Treat 2008, 110:453-463.
26. Huang C.H., Peng S., He L., Tsai Y.C., Boyd D.A., Hansen T.H., et al. Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther 2005, 12:1180-1186.
27. Wang B., Primeau T.M., Myers N., Rohrs H.W., Gross M.L., Lybarger L., et al. A single peptide-MHC complex positively selects a diverse and specific CD8 T cell repertoire. Science 2009, 326:871-874.
28. Flower D.R. Towards in silico prediction of immunogenic epitopes. Trends Immunol 2003, 24:667-674.
29. Liu W., Meng X., Xu Q., Flower D.R., Li T. Quantitative prediction of mouse class I MHC peptide binding affinity using support vector machine regression (SVR) models. BMC Bioinform 2006, 7:182.
30. Tammen H., Kreipe H., Hess R., Kellmann M., Lehmann U., Pich A., et al. Expression profiling of breast cancer cells by differential peptide display. Breast Cancer Res Treat 2003, 79:83-93.